Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective Sonoko Misawa 1 1Department of Neurology, Graduate School of Medicine, Chiba University Keyword: 新規治療 , インターフェロンβ , 脳由来神経栄養因子 , ミコフェノール酸モフェチル , 補体阻害薬 , novel therapeutic approach , interferon β , brain-derived neurotrophic factor , mycophenolate mofetil , complement inhibitors pp.1421-1428
Published Date 2015/11/1
DOI https://doi.org/10.11477/mf.1416200314
  • Abstract
  • Look Inside
  • Reference


Intravenous immunoglobulin (IVIg) and plasma exchange (PE) are of proven efficacy and are considered the standard therapy for Guillain Barré syndrome (GBS). However, some patients require artificial ventilation during the acute phase and experience long-lasting neurological deficits or symptoms. Currently, there is no established therapeutic intervention for GBS other than IVIg and PE, even though a number of compounds have been investigated. Clinical trials to investigate the efficacy and safety of a second IVIg or eculizumab are ongoing. Increased understanding of the pathophysiology of GBS is expected to contribute to the development of a novel therapeutic approach.

Copyright © 2015, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院